Skip to main content
OpenTrials
Completed

NCT Number: NCT04348110

Evaluation of Eye Health Benefits of Blueberry Chewable Tablets

To assess the efficacy of blueberry chewable tablets on Eye Health

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Eye

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chung Shan Medical University

Taichung, 402, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult men and women over 20 years old
  • Use 3C products over 6 hours per day
  • Symptoms of dry eyes or tired eyes
  • Tear Break-Up Time is 10 seconds less
  • No history of ocular surgery (strabismus surgery, refractive surgery etc.)

Exclusion criteria

  • Have systemic diseases affecting the front surface of the eyes.
  • Long-term use of drugs or eye drops that affect the condition of the front surface of the eyes
  • Long-term contact lens wear

Treatment and study plan

Placebo tablets

Dietary Supplement

consume 2 tablets per day for 8 weeks

Blueberry Chewable Tablets

Dietary Supplement

consume 2 tablets per day for 8 weeks

Other names: NutraView® Tablets

Primary outcomes

  1. Changes of Schirmer's test

    Time frame: 8 weeks

    Schirmer's test determines whether the eye produces enough tears to keep it moist. Units: mm (in 5minutes)

  2. Changes of tear meniscus height

    Time frame: 8 weeks

    Slit lamp Ocular Surface Analyzer is utilized to measure tear meniscus height. Units: mm

  3. Changes of non-invasive tear break-up time (NITBUT)

    Time frame: 8 weeks

    Ocular Surface Analyzer is utilized to measure non-invasive tear break-up time. Units: sec

  4. Tear break-up time (TBUT)

    Time frame: 8 weeks

    Slit lamp ocular Surface Analyzer is utilized to measure fist tear break-up time with slit lamp. Units: sec

  5. Changes of accommodation

    Time frame: 8 weeks

    Speedy-I is utilized to measure the accommodative micro fluctuation test of the ciliary muscle. Units: HFC

  6. Ocular Surface Disease Index (OSDI)

    Time frame: 8 weeks

    The Ocular Surface Disease Index (OSDI) is a 12-item scale for the assessment of symptoms related to dry eye disease and their effect on vision. Units: point

Secondary outcomes

  1. Changes of eye pressure

    Time frame: 8 weeks

    Eye pressure is measured in millimeters of mercury (mm Hg).

  2. Changes of Intraocular pressure (IOP)

    Time frame: 8 weeks

    Eye pressure is measured in millimeters of mercury (mm Hg). Units: mmHg

  3. Changes of Near point of convergence (NPC)

    Time frame: 8 weeks

    RAF rule were initiated in order to normalize NPC. Record as break/recovery. Units: cm

  4. Changes of Stereo vision

    Time frame: 8 weeks

    The Randot Stereotest is utilized to evaluate the depth perception. Units: sec

  5. Changes of binocular motor fusion

    Time frame: 8 weeks

    The test is utilized to evaluate to assess binocular motor fusion, specifically the extent to which a patient can maintain binocular single vision (BSV) in the presence of increasing vergence demands. Units: prism

  6. Changes of Amplitude of accommodation (AA)

    Time frame: 8 weeks

    The amplitude of accommodation is the maximum potential increase in optical power that an eye can achieve in adjusting its focus. It refers to a certain range of object distances for which the retinal image is as sharply focused as possible. Units: diopter

  7. Changes of Amplitude of Flipper facility

    Time frame: 8 weeks

    Vergence facility (VF) was measured by using a prism flipper to evaluate the ability of the fusional vergence at near with +/-2.00 flipper. Units: cpm

  8. Changes of Fundus photography

    Time frame: 8 weeks

    The fundus is the back of the eye and includes the retina, optic nerve, and retinal blood vessels.

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 15, 2020
Registry last updated
Jan 15, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.